HiLabs Secures $39M for AI-Powered Data Management Solutions
HiLabs' Series B funding round was led by Denali Growth Partners and Eight Roads Ventures and included participation from F-Prime Capital. In total, HiLabs has raised about $41 million.
HiLabs' Series B funding round was led by Denali Growth Partners and Eight Roads Ventures and included participation from F-Prime Capital. In total, HiLabs has raised about $41 million.
The Dublin-based pathology software and services provider will use the funds to support global growth and launch an on-demand, online pathology service in the U.S.
Mahmee raised $9.2 million in Series A funding led by Goldman Sachs Asset Management. The startup's CEO, Melissa Hanna, saw the raise as clear recognition of the progress Mahmee has made in tackling disparities in maternal care.
The San Francisco startup, which helps families find caregivers for their aging loved ones, will use the money from the round led by Javelin Venture Partners to expand and onboard additional caregivers.
Baltimore, Maryland-based startup Protenus has raised $11 million in a Series B round led by Kaiser Permanente Ventures and F-Prime Capital Partners. Arthur Ventures, LionBird Venture Capital and Cognosante Ventures also participated.
New York City-based Quartet has raised $40 million in a Series C round led by Polaris Partners and F-Prime Capital Partners. It also announced that it's teaming up with a payer: Horizon Blue Cross Blue Shield of New Jersey.
The fundraise will help the company expand its workforce, especially in sales, marketing and account management.
Vertical Venture Partners, which put an undisclosed amount of seed funding into Zipari in September 2014, led the round.
Most of the startups we’ve backed at Homebrew don’t rush to announce their funding. Not because they’re all operating in stealth or pre-product – in fact some already are earning $1M+ in revenue per annum. They just don’t feel the need to draw attention to themselves or alert possible competitors. And my sense is the trend carries […]
Daily, at-home blood glucose testing gives diabetics a way to monitor their glycemic control over the short term, and HbA1c testing gives a better picture long-term. Epinex Diagnostics Inc., a company developing a device to give doctors and patients an indication of their glycemic control over an intermediate term, revealed in a regulatory filing last […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.